Home GILD
77.89
  Price2.20%   +1.68
(After Hours: 77.85 -0.04 -0.05% )
loading

Gilead Sciences Stock (GILD) Latest News

May-31-23 04:17AM Top Stock Reports for FEMSA, NextEra Energy & SanofiZacks Investment Research
06:20AM Should You Invest in the VanEck Biotech ETF (BBH)?Zacks Investment Research
May-08-23 08:16AM American Express, Gilead Sciences And This US Oil Giant On CNBC's 'Final Trades'Benzinga
May-04-23 07:50AM Gilead Sciences Stock Has Only Done This in 1 of the Past 7 YearsThe Motley Fool
May-01-23 08:05AM Expert Ratings for Gilead SciencesBenzinga
Apr-28-23 03:34AM Gilead Sciences (GILD) Q1 2023 Earnings Call TranscriptThe Motley Fool
01:07AM Gilead's (GILD) Q1 Earnings Miss, Veklury Sales PlungeZacks Investment Research
Apr-28-23 08:17AM Gilead shares fall after mixed results, as weaker COVID-19 drug remand weighsMarketWatch
Apr-27-23 09:15AM Gilead shares fall after mixed results, as weaker COVID-19 drug remand weighsMarketWatch
09:33AM Debt Limit Bill Heads To Senate To Be RejectedBenzinga
Apr-27-23 05:30AM Better Buy: Pfizer vs. GileadThe Motley Fool
Apr-26-23 09:28AM Drug/Biotech Stocks' Q1 Earnings Due Apr 27: LLY, ABBV & MoreZacks Investment Research
Apr-25-23 10:01AM Incyte (INCY) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research
09:45AM This Supercharged Dividend King Stock Might Soon Run Out of SteamThe Motley Fool
Apr-25-23 07:45AM 2 Excellent Dividend Stocks to Buy for Less Than $100The Motley Fool
Apr-24-23 01:15AM S&P 500: Signs of a New Bull Market Keep MountingInvesting.com
07:27AM Big Tech Earnings & Economic Numbers: 3 Ways to Survive the Week AheadZacks Investment Research
Apr-21-23 12:55PM Will HIV and Oncology Propel Gilead's (GILD) Q1 Earnings?Zacks Investment Research
07:59AM Berkshire Hathaway, Gilead Sciences, Vertex Pharmaceuticals And A Break-Out Casino Stock Feature On CNBC's 'Final Trades'Benzinga
Apr-20-23 10:03AM Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseZacks Investment Research
Apr-12-23 03:00AM Expert Ratings for Gilead SciencesBenzinga
05:31AM Could Gilead Sciences Stock Help You Become a Millionaire?The Motley Fool
Apr-12-23 12:11PM DivHut Portfolio Update: March 2023Seeking Alpha
Apr-11-23 06:20AM Is SPDR Portfolio S&P 500 High Dividend ETF (SPYD) a Strong ETF Right Now?Zacks Investment Research
Apr-10-23 09:15AM If You Invested $10,000 in Gilead Sciences in 2013, This Is How Much You Would Have TodayThe Motley Fool
Apr-07-23 06:20AM Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?Zacks Investment Research
Apr-06-23 01:49AM Post-Pandemic Potential: Analysts Eye InflaRx COVID-19 Antibody For Market BreakthroughBenzinga
10:23AM Here's Why You Should Add Ligand (LGND) Stock to Your PortfolioZacks Investment Research
Apr-06-23 08:15AM 6 Reasons to Buy Gilead Sciences StockThe Motley Fool
Apr-05-23 03:09AM U.S. Wide-Moat Stocks On Sale - The April 2023 Heat MapSeeking Alpha
Apr-03-23 12:03PM Bristol Myers' (BMY) Breyanzi Gets Positive CHMP OpinionZacks Investment Research
06:20AM Should iShares Select Dividend ETF (DVY) Be on Your Investing Radar?Zacks Investment Research
Mar-31-23 06:20AM Should Franklin U.S. Low Volatility High Dividend Index ETF (LVHD) Be on Your Investing Radar?Zacks Investment Research
Mar-29-23 04:00AM Is It Time to Buy These Ultra-Cheap Dividend Stocks?The Motley Fool
03:42AM Why Are Cathie Wood's Ark ETFs Still Trailing Nasdaq Stocks?Benzinga
Mar-29-23 07:45AM Up 463%, This Sizzling Growth Stock Could Have a Lot More Room to RunThe Motley Fool
Mar-27-23 09:27AM Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend YieldsBenzinga
08:34AM Bunge, Gilead Sciences And A Famous Chocolate Maker On CNBC's 'Final Trades'Benzinga
Mar-27-23 06:20AM Should You Invest in the VanEck Biotech ETF (BBH)?Zacks Investment Research
Mar-23-23 01:51AM Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug ApprovalZacks Investment Research
06:20AM Is iShares Select Dividend ETF (DVY) a Strong ETF Right Now?Zacks Investment Research
Mar-23-23 06:20AM Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?Zacks Investment Research
Mar-22-23 02:38AM Gilead (GILD) Announces OS Data on Yescarta From ZUMA-7 StudyZacks Investment Research
10:07AM A Bull Market Is Coming: Load Up On These 3 Cheap Stocks TodayThe Motley Fool
Mar-22-23 06:20AM Should SPDR Russell 1000 Yield Focus ETF (ONEY) Be on Your Investing Radar?Zacks Investment Research
Mar-21-23 02:47AM Gilead (GILD) Exercises Option to License Nurix's CandidateZacks Investment Research
10:05AM Nurix's (NRIX) Stock Up Due to License Option Exercise by GileadZacks Investment Research
Mar-20-23 11:56AM First Republic Bank's stock plummets and Peloton's stock falls while New York Community Bank shares soar, and other stocks on the moveMarketWatch
Mar-16-23 12:10PM Gilead (GILD) Gains 34% in 12 Months: Will the Trend Sustain?Zacks Investment Research
Mar-15-23 06:20AM Is SPDR Russell 1000 Yield Focus ETF (ONEY) a Strong ETF Right Now?Zacks Investment Research
Gilead Sciences, Inc. discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a PI3K delta inhibitor for certain blood cancers; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and Lexiscan, an injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. In addition, the company offers Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B; AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Tango Therapeutics, Inc.; AELIX Therapeutics S.L.; and TARGET PharmaSolutions, Inc. The company was founded in 1987 and is headquartered in Foster City, California.
Cap:     |  Volume (24h):